Bepranemab
- Generic Name
- Bepranemab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2244960-75-4
- Unique Ingredient Identifier
- 9M1GV6L389
- Background
Bepranemab is a recombinant humanized Igg4P monoclonal antibody directed against human Tau.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 466
- Registration Number
- NCT04867616
- Locations
- 🇪🇸
Ah0003 40280, Sant Cugat Del Valles, Spain
🇪🇸Ah0003 40049, Sevilla, Spain
🇪🇸Ah0003 40453, Terrassa, Spain
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 25
- Registration Number
- NCT04185415
- Locations
- 🇬🇧
Psp003 40166, London, United Kingdom
🇩🇪Psp003 40278, Essen, Germany
🇪🇸Psp003 40267, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath